Adnan Elhammali1, Pierre Blanchard2, Alison Yoder1, Zhongxing Liao1, Xiadong Zhang3, X Ronald Zhu3, Pamela K Allen1, Melenda Jeter1, James Welsh1, Quynh-Nhu Nguyen4. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. 2. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Radiotherapy, Gustave Roussy Cancer Campus, Villejuif, France. 3. Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA. 4. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: qnnguyen@mdanderson.org.
Abstract
BACKGROUND & PURPOSE: We report disease control, survival, and toxicity in patients with advanced inoperable non-small cell lung cancer (NSCLC) receiving concurrent chemotherapy and intensity-modulated proton therapy (IMPT) at a single institution. MATERIAL AND METHODS: All patients were treated with IMPT with concurrent chemotherapy. Endpoints assessed were local, regional, and distant control, disease-free survival (DFS), and overall survival (OS). RESULTS: Fifty-one patients were enrolled with a median follow-up time of 23.0 months; 39 (76%) were treated with a simultaneous integrated boost to the gross tumor volume (GTV). The median GTV dose was 67.3 CGE and the median CTV dose was 60.0 CGE. Median OS and DFS times were 33.9 months and 12.6 months. The 3-year local control rate was 78.3%. Treatment was well tolerated, with a grade 3 toxicity rate of 18% (9 events: 4 esophagitis, 3 dermatitis, 1 esophageal stricture, and 1 fatigue) and no grade 4 or 5 toxicity. The most common grade 2 toxic effects were esophagitis (22 [43%]), dermatitis (16 [31%]), pain (15 [29%]), and fatigue (14 [27%]). CONCLUSIONS: Treatment of inoperable NSCLC with IMPT and concurrent chemotherapy achieves excellent disease control with tolerable toxicity.
BACKGROUND & PURPOSE: We report disease control, survival, and toxicity in patients with advanced inoperable non-small cell lung cancer (NSCLC) receiving concurrent chemotherapy and intensity-modulated proton therapy (IMPT) at a single institution. MATERIAL AND METHODS: All patients were treated with IMPT with concurrent chemotherapy. Endpoints assessed were local, regional, and distant control, disease-free survival (DFS), and overall survival (OS). RESULTS: Fifty-one patients were enrolled with a median follow-up time of 23.0 months; 39 (76%) were treated with a simultaneous integrated boost to the gross tumor volume (GTV). The median GTV dose was 67.3 CGE and the median CTV dose was 60.0 CGE. Median OS and DFS times were 33.9 months and 12.6 months. The 3-year local control rate was 78.3%. Treatment was well tolerated, with a grade 3 toxicity rate of 18% (9 events: 4 esophagitis, 3 dermatitis, 1 esophageal stricture, and 1 fatigue) and no grade 4 or 5 toxicity. The most common grade 2 toxic effects were esophagitis (22 [43%]), dermatitis (16 [31%]), pain (15 [29%]), and fatigue (14 [27%]). CONCLUSIONS: Treatment of inoperable NSCLC with IMPT and concurrent chemotherapy achieves excellent disease control with tolerable toxicity.
Authors: Olsi Gjyshi; Ting Xu; Adnan Elhammali; David Boyce-Fappiano; Stephen G Chun; Saumil Gandhi; Percy Lee; Aileen B Chen; Steven H Lin; Joe Y Chang; Anne Tsao; Carl M Gay; X Ronald Zhu; Xiaodong Zhang; John V Heymach; Frank V Fossella; Charles Lu; Quynh-Nhu Nguyen; Zhongxing Liao Journal: J Thorac Oncol Date: 2020-10-22 Impact factor: 15.609
Authors: Jingjing M Dougherty; Edward Castillo; Richard Castillo; Austin M Faught; Mark Pepin; Sean S Park; Chris J Beltran; Thomas Guerrero; Inga Grills; Yevgeniy Vinogradskiy Journal: J Appl Clin Med Phys Date: 2021-06-22 Impact factor: 2.102